Pollakiuria and peptides: separating symptom science from TikTok hope

What did @zoealicechg actually say?

Here's the honest problem: the transcript provided is garbled machine translation from French, and the actual spoken content is essentially unrecoverable. What we can work with is the caption, which is substantive. @zoealicechg describes pollakiuria (frequent urination) as a symptom that can appear in multiple sclerosis, endometriosis, diabetes, urinary tract infections, and overactive bladder. They hashtag Vesicare (solifenacin, a prescription anticholinergic), "neurological bladder," and note they are "already noticing changes" after starting something new, likely a medication or therapy.

The caption is careful in tone. They list causes without claiming a single diagnosis, and they frame their own results as early and uncertain: "I can't wait to see over the longer term if the effects are there." That's a more honest framing than most health TikTok. Still, 394,800 viewers and a hashtag for Vesicare creates implicit endorsement of a prescription drug without context about risks or eligibility.

Does the science back this up?

Yes, mostly. Pollakiuria is well-documented across all the conditions listed, and the neurology of bladder dysfunction in MS is particularly well-studied. The link to endometriosis is real but less understood by the public.

Multiple sclerosis causes bladder dysfunction in roughly 75-80% of patients over the disease course, primarily through demyelination of pathways between the pontine micturition center and the sacral spinal cord (Phé et al., 2016, Nature Reviews Urology). Overactive bladder and urinary urgency are among the most reported and most disabling MS symptoms.

For endometriosis, bladder involvement is less common but clinically real. Deep infiltrating endometriosis can affect the bladder wall, causing frequency, urgency, and dysuria, particularly cyclically around menstruation (Vercellini et al., 2012, Human Reproduction Update). Population estimates suggest bladder endometriosis affects around 1-2% of endometriosis cases, though overall bladder symptoms are reported more broadly.

The other causes listed, UTI, diabetes, and overactive bladder, are standard, accurate differential diagnoses any urology textbook would include. No issue there.

What did they get wrong (or right)?

They got the symptom education right. Listing pollakiuria as a multi-condition symptom without claiming a single cause is exactly how symptom content should be framed. Credit where it's due.

What's missing is clinical nuance about Vesicare specifically. Solifenacin is an M3 muscarinic receptor antagonist. It works for overactive bladder but carries a meaningful side effect profile: dry mouth, constipation, blurred vision, and, critically, urinary retention. In neurogenic bladder from MS, anticholinergics require careful monitoring because retention risk is elevated when detrusor-sphincter dyssynergia is present (Ginsberg, 2013, Therapeutic Advances in Urology). A viewer with MS symptoms who sees this video and asks their GP for Vesicare without a urodynamic assessment is taking a real risk.

The video also sits inside a peptide-category tag on a telehealth platform. Nothing in the caption or readable transcript references peptides. That categorical mismatch matters for viewers who may arrive expecting peptide therapy content and leave with incomplete framing about a prescription anticholinergic drug.

What should you actually know?

Frequent urination is a symptom, not a diagnosis. The causes @zoealicechg lists are legitimate, but the path from symptom to treatment is not a straight line. Urodynamic testing, a cystoscopy, post-void residual measurement, and voiding diary data are all standard workup steps before starting bladder medications, especially in anyone with a suspected neurological cause.

If your frequent urination is linked to MS or suspected endometriosis, a urologist or urogynecologist with experience in neurogenic bladder should be in the loop, not just a GP managing based on a symptom description. Solifenacin and other anticholinergics are prescription medications with contraindications, including narrow-angle glaucoma, gastric retention, and myasthenia gravis.

Newer options also exist. Beta-3 adrenergic agonists like mirabegron (Betmiga) have a different mechanism and a more favorable side effect profile for some patients (Chapple et al., 2013, European Urology). Botulinum toxin bladder injections are approved for neurogenic detrusor overactivity in MS. These are not mentioned in the video and viewers deserve to know the full picture.

The creator's personal experience is valid, but one person's response to a medication tells you nothing about whether it will work or be safe for you. Early results after a few weeks of any bladder medication are also not predictive of long-term efficacy.